SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2.88 |
| Enterprise Value ($M) | -0.68 |
| Book Value ($M) | 1.65 |
| Book Value / Share | 1.15 |
| Price / Book | 1.74 |
| NCAV ($M) | 1.65 |
| NCAV / Share | 1.15 |
| Price / NCAV | 1.74 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -5.73 |
| Return on Assets (ROA) | -18.86 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.70 |
| Current Ratio | 2.70 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 2.62 |
| Assets | 2.62 |
| Liabilities | 0.97 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Fortress Biotech, Inc. | 8.90 | -94.94 | |
| 13G | Armistice Capital, Llc | 7.21 | ||
| 13G/A | Davidow Robert L | 2.90 | -98.69 | |
| 13G/A | Sabby Management, Llc | 4.99 | 150.40 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,307 | 45,604 | 2.87 | |
| 1,905 | 6,228 | 30.59 | |
| 7,006 | 19,039 | 36.80 | |
| 4,624 | 17,274 | 26.77 | |
| 1,567 | 13,254 | 11.82 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ASRT – Assertio Holdings, Inc. | ATNF – 180 Life Sciences Corp. |
| ATOS – Atossa Therapeutics, Inc. | ATYR – aTyr Pharma, Inc. |
| AVTX – Avalo Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io